FDA Accepts NDA for Rivoceranib and Camrelizumab in 1L Unresectable HCC

Novel Cancer Vaccine Receives FDA Orphan Drug Designation in Cutaneous Melanoma   Videos
 
Reducing Secondary Diagnostic Delay Through the Breast Clinical Reporting and Data System Trending

Chronic Lymphocytic Leukemia/Small-Cell Lymphoma: 6-Year Follow-Up on SEQUOIA and ALPINE LTE1
This program explores evolving strategies in the management of chronic lymphocytic leukemia (CLL), with insights from Drs. Ian Flinn and Danielle Brander. The discussion focuses on the integration of BTK inhibitors and BCL2-targeted therapy, particularly zanubrutinib and venetoclax, highlighting their efficacy, safety, and practical application. Experts emphasize individualized treatment, balancing disease characteristics, comorbidities, and patient preferences, while considering therapy duration and the role of minimal residual disease (MRD)-guided approaches.

Featured Video
Six-Year Outcomes in CLL and SLL: Insights from the SEQUOIA and ALPINE Trials
In this segment, experts review 6-year follow-up data from the SEQUOIA and ALPINE studies in CLL and SLL, with a focus on efficacy, safety, and treatment selection in the modern era.

FDA Accepts BLA for Ivonescimab Regimen in Pretreated EGFR-Mutated NSCLC

FDA OKs Larger Nelarabine Vial in T-Cell Leukemia and Lymphoma Populations

New Career Center Video:  
Learn how to build and strengthen your oncology referral network with expert insights from Tarita Thomas, MD, PhD, MBA, FACRO. Watch Increasing Your Oncology Referral Network now.

Videos











Trending
Innovation, Elevation, and Empowerment Through Integrative Care in Oncology
 

Recent advances in ER-positive/HER2-negative MBC
Education Alert
Endocrine Therapies in ER-Positive/HER2-Negative MBC: Understanding Their Benefits and Limitations to Optimize Treatment Selection
0.50 CME / CE / ABIM MOC
Did you know that approximately 50% of breast cancer patients who have been exposed to an AI over time in the metastatic setting develop an ESR1 mutation?
 

Final overall survival and the association of pathological outcomes with event-free survival in MATTERHORN: A randomised, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel in resectable gastric / gastroesophageal junction adenocarcinoma
 
This Around the Practice program brings together a multidisciplinary panel to examine evolving perioperative strategies for resectable gastroesophageal and gastric cancers, with a particular focus on integrating systemic therapy, immunotherapy, and surgical planning. Panelists review emerging data from key studies, including the DFLOT regimen evaluated in the MATTERHORN trial, and discuss how these findings may influence real world care once regulatory decisions are finalized. Throughout the program, the experts highlight the importance of accurate staging, appropriate patient selection, and careful assessment of treatment tolerance when approaching complex early stage disease. The discussion incorporates practical considerations faced in both academic and community settings, including nutrition support, feeding access, performance status preservation, germline testing, and the coordination required for patients living at a distance from major centers.

Featured Video
 

Do you know when to use surgery and/or systemic treatment when managing neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (PN)s?
Education Alert
Optimizing Management of NF1-Associated Plexiform Neurofibromas: Expert Multidisciplinary Team Discussions
0.50 CPD
Experts discuss what you need to know to support your NF1-associated PNs patients.